“…MMS and CE-Office demonstrated lower costs than CE-OR in the institutional (MMS $2092.95, CE-Office $1376.45, CE-OR $2856.87) and insurance claims (MMS $2882.25, CE-Office $2043.98, CE-OR $5122.19) cohorts, which upholds previous findings describing the lower cost of outpatient surgery for melanoma 13 and nonmelanoma 17–19 skin cancer treatment. For example, Duncan and colleagues 13 found that reimbursements for pT1a melanoma treated with CE-OR and CE-Office were $2,612 and $1,419 respectively, although tumor location and surgical technique were not described. For outpatient surgery, MMS was more expensive than CE-Office in our cohort.…”